Arcturus Therapeutics

Arcturus therapeutics is a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and RNA-based therapeutics

/wp-content/themes/rewalk-parent/default_media/arcturus_space_1mbit_vbr2.mp4
News & Events
March 4, 2013
Arcturus Therapeutics Begins Operations in Janssen Labs
READ MORE
May 8, 2013
Arcturus Therapeutics Announces New Appointments to its Board of Directors and Scientific Advisory Board
READ MORE
June 1, 2013
Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding
READ MORE
June 3, 2013
With $1.3M in Seed Funding, Arcturus Adds to RNAi Hub in San Diego
READ MORE
October 1, 2020
Arcturus Therapeutics to Present at Guggenheim’s Vaccines and Infectious Diseases Conference
READ MORE
October 5, 2020
Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency
READ MORE
October 6, 2020
Recipharm signs agreement with Arcturus Therapeutics to support the manufacture of LUNAR®-COV19 (ARCT-021) vaccine candidate
READ MORE
October 30, 2020
Arcturus Therapeutics to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Nov 9, 2020
READ MORE
November 4, 2020
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
READ MORE
November 9, 2020
Arcturus Therapeutics Announces Positive Interim ARCT-021 (LUNAR-COV19) Phase 1/2 Study Results for Both Single Shot and Prime-boost Regimens, and Up to $220 Million in Additional Financial Commitments from Singapore
READ MORE
November 9, 2020
Arcturus Therapeutics Announces Third Quarter 2020 Financial Results and Positive Clinical Updates for ARCT-810 Phase I Study and Additional ARCT-021 Interim Data
READ MORE
November 30, 2020
Arcturus Therapeutics to Present at Upcoming Investor Conference
READ MORE
December 7, 2020
Arcturus Therapeutics Announces Initiation of Dosing ARCT-810 in Patients with Ornithine Transcarbamylase (OTC) Deficiency
READ MORE
December 7, 2020
Arcturus Therapeutics Announces Proposed Public Offering of Common Stock
READ MORE
December 7, 2020
Arcturus Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
READ MORE
December 28, 2020
Arcturus Therapeutics Received Approval from Singapore Health Sciences Authority to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate and Provides New and Updated Clinical and Preclinical Data
READ MORE
December 30, 2020
Arcturus Therapeutics to Advance ARCT-032, an Aerosolized LUNAR® mRNA-based Therapeutic, as a Development Candidate for Cystic Fibrosis Lung Disease
READ MORE
January 4, 2021
Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the United States
READ MORE
January 6, 2021
Arcturus Therapeutics to Present at Upcoming Investor Conference
READ MORE
February 11, 2021
Arcturus Therapeutics to Present at Upcoming Investor Conferences
READ MORE
February 19, 2021
Arcturus Therapeutics to Report Fourth Quarter and Year-End 2020 Financial Results and Provide Corporate Update on March 1, 2021
READ MORE
February 22, 2021
Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals
READ MORE
March 1, 2021
Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Positive Clinical Updates
READ MORE
March 30, 2021
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
READ MORE
https://arcturusrx.com/wp-content/uploads/2020/11/Arcturus_Lobby_Large.jpg
https://arcturusrx.com/wp-content/uploads/2020/11/Arcturus_Lobby_Small.jpg
https://arcturusrx.com/wp-content/uploads/2018/05/18arct1244fxF.jpg
https://arcturusrx.com/wp-content/uploads/2018/05/18arct1244fxF_230.jpg
https://arcturusrx.com/wp-content/uploads/2020/11/ArcBuilding_Final.jpg
https://arcturusrx.com/wp-content/uploads/2020/11/building_external_thumbnail.jpg
https://arcturusrx.com/wp-content/uploads/2018/05/18arct1055fxF.jpg
https://arcturusrx.com/wp-content/uploads/2018/05/18arct1055fxF_230.jpg
https://arcturusrx.com/wp-content/uploads/2016/05/main-visual-office-exterior.jpg
https://arcturusrx.com/wp-content/uploads/2020/11/main_office_exterior_thumbnail.jpg
https://arcturusrx.com/wp-content/uploads/2016/05/main-visual-office-interior-tag-line.jpg
https://arcturusrx.com/wp-content/uploads/2020/11/building_tagline_thumbnail.jpg
https://arcturusrx.com/wp-content/uploads/2020/09/20arctlab286fxFNLLo-scaled.jpg
https://arcturusrx.com/wp-content/uploads/2020/11/20arctlab286fxFNLLo_thumbnail.jpg
https://arcturusrx.com/wp-content/uploads/2020/09/20arctlab228fxFNLLo-scaled.jpg
https://arcturusrx.com/wp-content/uploads/2020/11/20arctlab228fxFNLLo_thumbnail.jpg
https://arcturusrx.com/wp-content/uploads/2020/09/20arctlab206fxFNLLo-scaled.jpg
https://arcturusrx.com/wp-content/uploads/2020/11/20arctlab206fxFNLLo_thumbnail.jpg

LUNAR®-mediated delivery of RNA into cells

LUNAR® particles associate with the cell membrane of a target cell of interest and quickly enter the cell via endocytosis.

Upon entering the cytosol, the LUNAR® formulations then become trapped in the endosomes.

With increased acidity as the endosome ages, a pH-mediated disruption enables release of the RNA payload following rapid biodegradation of the LUNAR®components.

Once release of the RNA into the cytosol occurs, the translational machinery can interact with the RNA and processing and/or trafficking can then take place to make functional protein.

LUNAR® lipid mediated delivery enables delivery of RNA medicines.